158.30
0.30 (0.19%)
| Previous Close | 158.00 |
| Volume | 1,092,496 |
| Price / Earnings (Forward) | 12.92 |
| Price / Sales | 4.53 |
| Price / Book | 6.13 |
| 52 Weeks Range |
| Profit Margin | -11.49% |
| Operating Margin (TTM) | 3.04% |
| Diluted EPS (TTM) | -2.11 |
| Quarterly Revenue Growth (YOY) | 20.20% |
| Total Debt/Equity (MRQ) | 2,358.25% |
| Current Ratio (MRQ) | 3.04 |
| Operating Cash Flow (TTM) | -45.11 M |
| Levered Free Cash Flow (TTM) | 223.09 M |
| Return on Assets (TTM) | -1.79% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Alnylam Pharmaceuticals, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 4.3 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Relative Valuation | NA |
| Financial Health | -0.5 |
| Macro Environment | -2.8 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | -0.23 |
Select this tab to load the latest available analysis.
|
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam’s commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam’s partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Insiders | 3.81% |
| % Held by Institutions | 97.56% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Capital Research Global Investors | 30 Jun 2026 | 9,750,699 |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |